Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Dual NRT

PreclinicalSmall molecule

MMassachusetts General Hospital

Dual NRT is one of 36 small molecule programs targeting Recovery. It is currently in Preclinical.

2

Indications

1

Total Trials

1

Active Trials

35

Competitors

Pipeline

Status by Indication[3][1]

Indication

RecoveryNot yet recruiting

Opioid Use DisorderActive, not recruiting

RecoveryPreclinical

Not yet recruiting

Opioid Use DisorderPreclinical

Active, not recruiting

Competition

Competitive Landscape

116 competitors in Opioid Use Disorder

#DrugCompanyPhaseTrials

Revia

Belsomra

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Epidiolex

Jazz Pharmaceuticals

Dayvigo

Ozempic

Vraylar

Mounjaro

Victoza

Diamox

Buprenorphine/naloxone

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

PreclinicalNot yet recruiting

Recovery

NCT06965153

Clinical

Trials by Indication[1]

Recovery1 trial

Peer Recovery Coaching for Promoting Tobacco Abstinence in People With Opioid Use Disorder

Not yet recruiting·MMassachusetts General Hospital·Preclinical·NCT06965153·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dual NRT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dual NRT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dual NRT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Massachusetts General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMassachusetts General Hospital

Related News